Efficacy of Ajwain gel in chemotherapy-induced peripheral neuropathy

Effectiveness of Ajwain gel in treatment of chemotherapy-induced peripheral neuropathy in cancer patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220130053877N2

Enrollment

Registered

2024-01-28

Start date

2023-09-23

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy induced peripheral neuropathy. Drug-induced polyneuropathy

Interventions

Intervention 1: Intervention group: Ajwain seed extracted gel use for 1 month to reduce Chemotherapy induced peripheral neuropathy symptoms. Drugs (Ajwain placebo) prepared in white tubes and coded 1-

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Symptoms of peripheral neuropathy Breast cancer patients History of chemotherapy Age between 18 and 60 Interest to participate in trial

Exclusion criteria

Exclusion criteria: Hypersensitivity to Ajwain Using SSRI, SNRI or TCA drugs Renal or liver failure Diabetes Musculoskeletal disorder such as: disc herniation and carpal tunnel syndrome Deterioration of the patient Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: In the beginning, day 15 and 30 of trial. Method of measurement: By Using Common Terminology Criteria for Adverse Events Version 5.;Pain. Timepoint: In the beginning, day 15 and 30 of trial. Method of measurement: By using Visual Analogue Scale.;Motor symptoms. Timepoint: In the beginning, day 15 and 30 of trial. Method of measurement: By using Common Terminology Criteria for Adverse Events Version 5.;Sensory symptoms (paresthesia & tingling). Timepoint: In the beginning, day 15 and 30 of trial. Method of measurement: By Using Common Terminology Criteria for Adverse Events Version 5.	—

Measure

Time frame

Pain. Timepoint: In the beginning, day 15 and 30 of trial. Method of measurement: By Using Common Terminology Criteria for Adverse Events Version 5.;Pain. Timepoint: In the beginning, day 15 and 30 of trial. Method of measurement: By using Visual Analogue Scale.;Motor symptoms. Timepoint: In the beginning, day 15 and 30 of trial. Method of measurement: By using Common Terminology Criteria for Adverse Events Version 5.;Sensory symptoms (paresthesia & tingling). Timepoint: In the beginning, day 15 and 30 of trial. Method of measurement: By Using Common Terminology Criteria for Adverse Events Version 5.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeed Araby aliabad

Shiraz University of Medical Sciences

araby.saeed69@gmail.com+98 71 3647 4320

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026